Page last updated: 2024-11-05

2-methyl-4-chlorophenoxyacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Methyl-4-chlorophenoxyacetic Acid: A powerful herbicide used as a selective weed killer. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(4-chloro-2-methylphenoxy)acetic acid : A chlorophenoxyacetic acid that is (4-chlorophenoxy)acetic acid substituted by a methyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7204
CHEMBL ID394657
CHEBI ID50099
SCHEMBL ID117877
MeSH IDM0013151

Synonyms (171)

Synonym
metaxon
cornox-m
2m-4kh
kilsem4k-2m
acetic acid, [(4-chloro-o-tolyl)oxy]-
agritox
rhomene
raphone
rhomenc
(2-methyl-4-chlorophenoxy)acetic acid
mephanac
bordermaster
2,4-mcpa
herbicide m
agroxone
rhonox
(4-chloro-o-cresoxy)acetic acid
nsc-2351
b-selektonon m
hedarex m
mcpa
dicopur-m
leuna m
chiptox
linormone
anicon m
agroxon
dikotex
zelan
dikotes
trasan
hedapur m 52
94-74-6
(4-chloro-2-methylphenoxy)acetic acid
chwastox
[(4-chloro-o-tolyl)oxy]acetic acid
emcepan
(4-chloro-o-toloxy)acetic acid
2m-4ch
anicon kombi
nsc2351
okultin m
wln: qv1or dg b1
hedonal m
2-methyl-4-chlorphenoxyessigsaeure
netazol
hornotuho
krezone
acetic acid, (4-chloro-2-methylphenoxy)-
2-methyl-4-chlorophenoxyacetic acid
((4-chloro-o-tolyl)oxy)acetic acid
CHEBI:50099 ,
leyspray
ustinex
ccris 1022
mcpa [chlorophenoxy herbicides]
chwastox 30
kwas 4-chloro-2-metylofenoksyoctowy [polish]
shamrox
einecs 202-360-6
nsc 2351
acetic acid, ((4-chloro-o-tolyl)oxy)-
hsdb 1127
epa pesticide chemical code 030501
phenoxylene 50
caswell no. 557c
dicotex
empal
legumex db
weedone mcpa ester
4-chloro-o-cresoxyacetic acid
soviet technical herbicide 2m-4c
4k-2m
kyselina 4-chlor-2-methylfenoxyoctova [czech]
vesakontuho mcpa
methylchlorophenoxyacetic acid
acme mcpa amine 4
phenoxylene plus
2-methyl-4-chlorphenoxyessigsaeure [german]
vacate
brn 2051752
razol dock killer
m 40
chwastox extra
phenoxylene super
mcpa [bsi:iso]
bh mcpa
4-chloro-o-toloxyacetic acid
banvel m
kilsem
4-chloro-2-methylphenoxyacetic acid
seppic mmd
brominal m & plus
hormotuho
smr000066149
MLS000054403 ,
2-(4-chloro-2-methyl-phenoxy)acetic acid
STK373011
inchi=1/c9h9clo3/c1-6-4-7(10)2-3-8(6)13-5-9(11)12/h2-4h,5h2,1h3,(h,11,12
NCGC00036782-02
NCGC00036782-03
MLS000881211
4-chloro-2-methylphenoxyacetic acid, technical, >=95.0% (t)
CHEMBL394657 ,
2-(4-chloro-2-methylphenoxy)acetic acid
bdbm50213927
((4-chloro-o-tolyl)oxy)acetic acid,
cornox
AKOS000119470
NCGC00036782-05
NCGC00036782-04
BBL002969
C18528
tox21_300746
dtxsid4024195 ,
dtxcid304195
NCGC00259821-01
cas-94-74-6
NCGC00254652-01
tox21_202272
HMS2232I09
kyselina 4-chlor-2-methylfenoxyoctova
acetic acid, 2-(4-chloro-2-methylphenoxy)-
d888c394vo ,
kwas 4-chloro-2-metylofenoksyoctowy
unii-d888c394vo
BP-11952
FT-0618033
hedapur m
mcpa [hsdb]
mecaphar
mcpa [mi]
dicopur m
mcpa [iso]
HMS3372K10
(4-chloro-2-methyl-phenoxy)-acetic acid
aceticacid, 2-(4-chloro-2-methylphenoxy)-
AB00425449-11
SCHEMBL117877
KS-5262
dow mcp amine weed killer
weedar mcpa
agricorn 500 ii
cekherbex
atlas mcpa
selektonon m
2m-4c
acetic acid, (4-chloro-o-toloxy)-
agritox 50
methyl chlorophenoxy acetic acid
albar-m
campbell's mcpa 25, 50
W-100186
OPERA_ID_1492
mfcd00004306
mcpa, pestanal(r), analytical standard
Z56824184
mcpa 10 microg/ml in acetonitrile
mcpa 100 microg/ml in acetonitrile
mcpa 2000 microg/ml in methyl tert-butyl ether
2-methyl-4-chlorophenoxyaceticacid
Q149413
EN300-16931
AMY3557
(4-chloro-2-methylphenoxy)ethanoic acid
H10107
4-chloro-2-methylbenzoxyacetic acid
CAA44806
CS-0012872
HY-B0859
(4-chloro-2-methylphenoxy)aceticacid-13c6

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No adverse effect of the gallbladder, except for papillary proliferation, was noted at all the dose levels of the experimental groups."( Chronic toxicity of 2-methyl-4-chlorophenoxyacetic acid (MCPA) in mice.
Takagi, S, 1990
)
0.6
" There may also be an impact at greater distances from treated plots, especially in the case of compounds that are slow to degrade such as MITC (methyl isothiocyanate), the active toxic moiety generated in soil from metham sodium."( Possible side effects of airborne pesticides on fungi and vascular plants in The Netherlands.
Canters, KJ; de Jong, FM; van der Voet, E, 1995
)
0.29
"5,6-Dichloro-4-thia-5-hexenoic acid (DCTH) is toxic to rat liver and kidney mitochondria and is cytotoxic to isolated rat hepatocytes."( Nephrotoxicity and hepatotoxicity of 5,6-dichloro-4-thia-5-hexenoic acid: evidence for fatty acid beta-oxidation-dependent bioactivation.
Anders, MW; Baggs, RB; Fitzsimmons, ME, 1994
)
0.29
" Algal and lemna test show that isoproturon and terbuthylazine are both much more toxic than mecoprop and metamitron."( Biodegradation in laboratory activated sludge plants and aquatic toxicity of herbicides.
Lind, G; Metzner, G; Nitschke, L; Schüssler, W; Wilk, A, 1999
)
0.3
" The presence of any toxic chemical that interfered with the cells' metabolism resulted in a quantitative decrease in bioluminescence."( Design and application of a biosensor for monitoring toxicity of compounds to eukaryotes.
Glover, LA; Hollis, RP; Killham, K, 2000
)
0.31
" Consistent with the concept that the toxic form is the liposoluble undissociated form, at values close to their pK(a) (3."( Toxicity of chlorinated phenoxyacetic acid herbicides in the experimental eukaryotic model Saccharomyces cerevisiae: role of pH and of growth phase and size of the yeast cell population.
Cabral, MG; Sá-Correia, I; Teixeira, MC; Viegas, CA, 2003
)
0.32
"5 times controls) increases in SCE were observed in vivo in the hamster at toxic or maximum tolerated dose levels."( Review of the genotoxicity of 4-chloro-2-methylphenoxyacetic acid.
Elliott, B, 2005
)
0.33
"Administration of MCPA did not cause mortality and had no adverse effects on hematological parameters of animals."( Adverse effects of herbicide MCPA on dogs in a 90 day toxicological study.
Flaskárová, E; Hózová, R; Sadlonová, I, 2006
)
0.33
" We determined whether the surfactant in the formulation was the chemical responsible for the toxic symptom in this patient."( Surfactant toxicity in a case of (4-chloro-2-methylphenoxy) acetic acid herbicide intoxication.
Gil, HW; Hong, SY; Hwang, I; Kim, JS; Lee, JW; Song, HY, 2015
)
0.42
"The surfactant PTE was likely the chemical responsible for the toxic symptom in our patient."( Surfactant toxicity in a case of (4-chloro-2-methylphenoxy) acetic acid herbicide intoxication.
Gil, HW; Hong, SY; Hwang, I; Kim, JS; Lee, JW; Song, HY, 2015
)
0.42
" Next to growth inhibition, given as EC50, changes in the isomerisation of cis to trans unsaturated fatty acids were applied as proxy for cellular stress adaptation to toxic substances."( Toxicity of synthetic herbicides containing 2,4-D and MCPA moieties towards Pseudomonas putida mt-2 and its response at the level of membrane fatty acid composition.
Chrzanowski, Ł; Heipieper, HJ; Piotrowska, A; Syguda, A, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" All methods gave recoveries >80% for the pesticide mixture, but extraction with sodium hydroxide in combination with solid-phase preconcentration was used for further recovery tests with soils of different properties spiked at four herbicide concentration levels (0."( Determination of bentazone, dichlorprop, and MCPA in different soils by sodium hydroxide extraction in combination with solid-phase preconcentration.
Christiansen, A; Thorstensen, CW, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The effect of ageing on the bioavailability and sorption of the herbicides atrazine and mecoprop was studied in soil and aquifer chalk sampled at an agricultural field near Aalborg, Denmark."( Mineralization of aged atrazine and mecoprop in soil and aquifer chalk.
Aamand, J; Johannesen, H; Kristensen, GB, 2001
)
0.31
"The effect of aging of the herbicides atrazine, terbuthylazine, 2,4-D, and mecoprop on their bioavailability to degrading microorganisms was studied in soil and aquifer sediment."( Mineralization of aged atrazine, terbuthylazine, 2,4-D, and mecoprop in soil and aquifer sediment.
Aamand, J; Johannesen, H, 2003
)
0.32
"High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat."( 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
Aldcroft, C; Baettig, U; Barker, L; Beer, D; Bhalay, G; Bidlake, L; Brown, Z; Budd, D; Campbell, E; Cox, B; Dubois, G; Everatt, B; Harrison, D; Leblanc, CJ; Manini, J; Profit, R; Sandham, DA; Stringer, R; Thompson, KS; Turner, KL; Tweed, MF; Walker, C; Watson, SJ; Whitebread, S; Williams, G; Willis, J; Wilson, C, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves in which the block of GCl by the S-(-) isomer was evaluated in the presence of the R-(+) isomer (3-10 microM) clearly showed an antagonistic interaction between the two enantiomers, with an increase in the S-(-) concentration for half-maximal block."( Opposite effects of enantiomers of clofibric acid derivative on rat skeletal muscle chloride conductance: antagonism studies and theoretical modeling of two different receptor site interactions.
Bryant, SH; Conte Camerino, D; De Luca, A; Tortorella, V; Tricarico, D; Wagner, R, 1992
)
0.28
" Groups of male and female F1b animals were then dosed as were their parents for 10 weeks postweaning, and the breeding was repeated to produce F2a and F2b animals."( Reproductive toxicity of MCPA (4-chloro-2-methylphenoxyacetic acid) in the rat.
Bellet, EM; Hellwig, J; Pigott, G; van Ravenzwaay, B,
)
0.13
" In an attempt to explain the difference in toxicology between these species, rats and dogs were orally dosed with (14C)-MCPA at 5 or 100 mgkg(-1) and plasma toxicokinetics, rates and routes of excretion and biotransformation were investigated."( Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog.
Hardwick, TD; Lappin, GJ; Pigott, GH; Stow, R; Van Ravenzwaay, B, 2002
)
0.31
" The data, although apparently influenced by season, showed an inverted or U-shaped dose-response pattern for reduced litter size, with the low end of the dose range producing the greatest decrease in the number of live pups born."( Developmental toxicity of a commercial herbicide mixture in mice: I. Effects on embryo implantation and litter size.
Cavieres, MF; Jaeger, J; Porter, W, 2002
)
0.31
" Rats dosed at 100 mg/kg showed similar absorption kinetics but apparent saturation of urinary excretion led to a prolonged elimination phase."( Absorption, distribution, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rats.
Leibold, E; Pigott, G; van Ravenzwaay, B, 2004
)
0.32
"The impact of the strain on the metabolite profile of plasma samples in rats dosed with 2500 ppm 2-methyl-4-chlorophenoxyacetic acid (MCPA acid) or 45 mg/kg bw/day 4-chloro-3-nitroaniline (4C3N) for 4 weeks was evaluated."( Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies.
Fabian, E; Herold, M; Kamp, H; Krennrich, G; Leibold, E; Looser, R; Mellert, W; Prokoudine, A; Strauss, V; van Ravenzwaay, B; Walk, T; Wiemer, J, 2009
)
0.57
" Effects of pH, contact time, initial concentration and sorbent dosage on the sorption of the herbicide were investigated."( Sorption capacity of mesoporous metal oxides for the removal of MCPA from polluted waters.
Addorisio, V; Esposito, S; Sannino, F, 2010
)
0.36
" The potential risk of contamination depended on the actual dosage of each herbicide applied by farmers to their rice fields."( Contamination of rice field water with sulfonylurea and phenoxy herbicides in the Muda Irrigation Scheme, Kedah, Malaysia.
Ismail, BS; Prayitno, S; Tayeb, MA, 2015
)
0.42
" In fat tissues, the key genes Lep, Nmb and Nmbr were altered in high dosed offspring, and were differentially expressed between sexes."( Effects on metabolic parameters in young rats born with low birth weight after exposure to a mixture of pesticides.
Axelstad, M; Christiansen, S; Hass, U; Mandrup, K; Ramhøj, L; Svingen, T; Vinggaard, AM, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
synthetic auxinA synthetic compound exhibiting auxin activity.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
phenoxy herbicideAny member of the class of herbicides whose members contain a phenoxy or substituted phenoxy group.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chlorophenoxyacetic acidA monocarboxylic acid that is phenoxyacetic acid in which at least one of the phenyl hydrogens is replaced by chlorine.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485341
LuciferasePhotinus pyralis (common eastern firefly)Potency59.74480.007215.758889.3584AID1224835; AID588342
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.21560.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency60.75780.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency43.77800.000221.22318,912.5098AID743036
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.18810.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.87240.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.91090.000229.305416,493.5996AID588514; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.36900.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00160.023723.228263.5986AID588543
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.13950.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
gemininHomo sapiens (human)Potency0.07750.004611.374133.4983AID624296; AID624297
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.07941.000010.475628.1838AID901
TAR DNA-binding protein 43Homo sapiens (human)Potency7.94331.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin D2 receptorHomo sapiens (human)Ki10.00000.00060.49131.4000AID308153
Prostaglandin D2 receptor 2Homo sapiens (human)Ki10.00000.00060.67358.0000AID308151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin D2 receptorHomo sapiens (human)
male sex determinationProstaglandin D2 receptorHomo sapiens (human)
sleepProstaglandin D2 receptorHomo sapiens (human)
mast cell degranulationProstaglandin D2 receptorHomo sapiens (human)
adenosine metabolic processProstaglandin D2 receptorHomo sapiens (human)
cellular response to prostaglandin D stimulusProstaglandin D2 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin D2 receptorHomo sapiens (human)
inflammatory responseProstaglandin D2 receptorHomo sapiens (human)
chemotaxisProstaglandin D2 receptor 2Homo sapiens (human)
immune responseProstaglandin D2 receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin D2 receptor 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayProstaglandin D2 receptor 2Homo sapiens (human)
calcium-mediated signalingProstaglandin D2 receptor 2Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayProstaglandin D2 receptor 2Homo sapiens (human)
negative regulation of male germ cell proliferationProstaglandin D2 receptor 2Homo sapiens (human)
neuropeptide signaling pathwayProstaglandin D2 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
prostaglandin J receptor activityProstaglandin D2 receptorHomo sapiens (human)
prostaglandin D receptor activityProstaglandin D2 receptorHomo sapiens (human)
protein bindingProstaglandin D2 receptorHomo sapiens (human)
prostaglandin J receptor activityProstaglandin D2 receptor 2Homo sapiens (human)
G protein-coupled receptor activityProstaglandin D2 receptor 2Homo sapiens (human)
prostaglandin D receptor activityProstaglandin D2 receptor 2Homo sapiens (human)
prostaglandin F receptor activityProstaglandin D2 receptor 2Homo sapiens (human)
neuropeptide bindingProstaglandin D2 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
membraneProstaglandin D2 receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptor 2Homo sapiens (human)
plasma membraneProstaglandin D2 receptor 2Homo sapiens (human)
neuron projectionProstaglandin D2 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID308153Binding affinity at prostanoid DP receptor2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1212049Half life in rat plasma at 5 mg/kg2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, in rats and dogs.
AID1212048Half life in dog plasma at 5 mg/kg2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, in rats and dogs.
AID308151Displacement of [3H]PG2 from human CRTh2 receptor expressed in CHO cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1212050Half life in human plasma at 5 mg/kg2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, in rats and dogs.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (473)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (21.78)18.7374
1990's75 (15.86)18.2507
2000's121 (25.58)29.6817
2010's134 (28.33)24.3611
2020's40 (8.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.05 (24.57)
Research Supply Index6.22 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews15 (3.00%)6.00%
Case Studies21 (4.20%)4.05%
Observational0 (0.00%)0.25%
Other464 (92.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]